ExThera Medical and Asahi Kasei Medical Enter into Partnership to Expand Reach of Treatment for the Critically Ill
Retrieved on:
Tuesday, December 21, 2021
Health, Medical Devices, Infectious Diseases, General Health, Research, Science, Biotechnology, Mortality, Blood, Bloodstream infections, Life, COSA, Ammonia, Jean-Louis Vincent, Virus, Communication, Heparin, Patient, Sepsis, CE, Fungus, News, CEO, DARPA, Infection, Bacteria, Adsorption, Therapy, Pandemic, COVID-19, European, NDT, Solution, ICU, Hospital, Treatment, Dialysis, Health care, Multimedia, Person, EUA, FDA, Partnership, Pharmaceutical industry, Mobile phone, EU, Seraph, Asahi Kasei and Asahi Kasei Medical, ExThera Medical Corporation, Seraph 100, ASAHI KASEI AND ASAHI KASEI MEDICAL, EXTHERA MEDICAL CORPORATION, SERAPH 100
ExThera Medical and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for ExThera's Seraph 100 Microbind Affinity Blood Filter (Seraph 100).
Key Points:
- ExThera Medical and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for ExThera's Seraph 100 Microbind Affinity Blood Filter (Seraph 100).
- Per the agreement structure, ExThera Medical and Asahi Kasei Medical will collaborate to obtain regulatory approval of Seraph 100 for commercialization in Japan.
- "ExTheras partnership with Asahi Kasei Medical is an important milestone in our collaborative ongoing fight against life threatening pathogens.
- ExThera Medicals extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from severe infections.